Latest by Sean R. Hosein
Bictegravir-containing regimens performed well over 48 weeks, with more than 90% of participants achieving a viral load less than 50 copies/mL.
The experimental integrase inhibitor being developed by Gilead Sciences is currently in phase III clinical trials.
The new nucleoside analogue GS-9131 may be useful as part of regimens for people who have strains of drug-resistant HIV.
At the recent Conference on Retroviruses and Opportunistic Infections, researchers presented data about 5 new anti-HIV compounds in development.
A capsid inhibitor could affect three parts of HIV's life cycle and could be used by itself in the prevention of HIV infection. However, much work lies ahead before this drug's developer can be certain about that.
In a small cross-sectional study researchers found a link between the use of integrase inhibitors and the presence of low testosterone, but they may have inadvertently arrived at this conclusion.
A review of key ideas about male sexual dysfunction in HIV-positive men.
Researchers found that, overall, while HIV-positive people had increased life expectancy since 1996, it was substantially less than that of the average HIV-negative person of the same gender.
In a randomized clinical trial, researchers found that rates of HIV testing doubled among gay and bisexual men who were given self-test kits.
A recent survey uncovers some barriers that explain why not all patients have been prescribed antiretroviral therapy.